Lipid-based nanocarriers for breast cancer treatment – comprehensive review

References

• Aapro MS. (2001). Adjuvant therapy of primary breast cancer: a review of key findings from the 7th international conference, St. Gallen, February 2001. The Oncologist 6:376–85
   PubMedGoogle Scholar
• Acevedo-Morantes CY, Acevedo-Morantes MT, Suleiman-Rosado D, Ramírez-Vick JE. (2013). Evaluation of the cytotoxic effect of camptothecin solid lipid nanoparticles on MCF7 cells. Drug Deliv 20:338–48
   PubMed Web of Science ®Google Scholar
• Aderem A, Underhill DM. (1999). Mechanisms of phagocytosis in macrophages. Annu Rev Immunol 17:593–623
   PubMed Web of Science ®Google Scholar
• Alavi SE, Esfahani MKM, Alavi F, et al. (2013). Drug delivery of hydroxyurea to breast cancer using liposomes. Indian J Clin Biochem 28:299–302
   PubMedGoogle Scholar
• Allen TM, Martin FJ. (2004). Advantages of liposomal delivery systems for anthracyclines. Semin Oncol 31:5–15
   PubMed Web of Science ®Google Scholar
• Anon. (2015). Facts C. Cancer Facts Figures. [Online] Available at: http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-(0445)52.pdf [last accessed 20 Apr 2015]
   Google Scholar
• Aznar MÁ, Lasa-Saracíbar B, de Mendoza AE.-H., Blanco-Prieto MJ. (2013). Efficacy of edelfosine lipid nanoparticles in breast cancer cells. Int J Pharm 454:720–6
   PubMed Web of Science ®Google Scholar
• Barrajón-Catalán E, Menéndez-Gutiérrez MP, Falco A, et al. (2010). Selective death of human breast cancer cells by lytic immunoliposomes: correlation with their HER2 expression level. Cancer Lett 290:192–203
   PubMed Web of Science ®Google Scholar
• Bedi D, Musacchio T, Fagbohun OA, et al. (2011). Delivery of siRNA into breast cancer cells via phage fusion protein-targeted liposomes. Nanomed Nanotechnol Biol Med 7:315–23
   PubMed Web of Science ®Google Scholar
• Benner SE, Fetting JH, Brenner MH. (1994). A stopping rule for standard chemotherapy for metastatic breast cancer: lessons from a survey of Maryland medical oncologists. Cancer Invest 12:451–5
   PubMed Web of Science ®Google Scholar
• Bertrand N, Wu J, Xu X, et al. (2014). Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 66:2–25
   PubMed Web of Science ®Google Scholar
• Catania A, Barrajón-Catalán E, Nicolosi S, et al. (2013). Immunoliposome encapsulation increases cytotoxic activity and selectivity of curcumin and resveratrol against HER2 overexpressing human breast cancer cells. Breast Cancer Res Treat 141:55–65
   PubMed Web of Science ®Google Scholar
• Coleman R, Biganzoli L, Canney P, et al. (2006). A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). Eur J Cancer 42:882–7
   PubMed Web of Science ®Google Scholar
• Cuzick J, Powles T, Veronesi U, et al. (2003). Overview of the main outcomes in breast-cancer prevention trials. Lancet 361:296–300
   PubMed Web of Science ®Google Scholar
• Dadgar N, Alavi SE, Esfahani MKM, Akbarzadeh A. (2013). Study of toxicity effect of pegylated nanoliposomal artemisinin on breast cancer cell line. Indian J Clin Biochem 28:410–12
   PubMedGoogle Scholar
• Dagar S, Krishnadas A, Rubinstein I, et al. (2003). VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: in vivo studies. J Control Release 91:123–33
   PubMed Web of Science ®Google Scholar
• Davda J, Labhasetwar V. (2002). Characterization of nanoparticle uptake by endothelial cells. Int J Pharm 233:51–9
   PubMed Web of Science ®Google Scholar
• Doherty GJ, McMahon HT. (2009). Mechanisms of endocytosis. Annu Rev Biochem 78:857–902
   PubMed Web of Science ®Google Scholar
• Duo J, Ying, G-G, Wang G-W, Zhang, L. (2012). Quercetin inhibits human breast cancer cell proliferation and induces apoptosis via Bcl-2 and Bax regulation. Mol Med Report 5:1453–6
   PubMed Web of Science ®Google Scholar
• Esposito E, Mariani P, Ravani L, et al. (2012). Nanoparticulate lipid dispersions for bromocriptine delivery: characterization and in vivo study. Eur J Pharm Biopharm 80:306–14
   PubMed Web of Science ®Google Scholar
• Fang Y-P, Lin Y-K, Su Y-H, Fang J-Y. (2011). Tryptanthrin-loaded nanoparticles for delivery into cultured human breast cancer cells, MCF7: the effects of solid lipid/liquid lipid ratios in the inner core. Chem Pharm Bull (Tokyo) 59:266–71
   PubMed Web of Science ®Google Scholar
• Fenske DB, Cullis PR. (2008). Liposomal nanomedicines. Expert Opin Drug Deliv 5:25–44
   PubMed Web of Science ®Google Scholar
• Fisher B, Brown A, Mamounas E, et al. (1997). Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483–93
   PubMed Web of Science ®Google Scholar
• Fisher B, Costantino JP, Wickerham DL, et al. (2005). Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97:1652–62
   PubMed Web of Science ®Google Scholar
• Fontana G, Maniscalco L, Schillaci D, et al. (2005). Solid lipid nanoparticles containing tamoxifen characterization and in vitro antitumoral activity. Drug Delivery 12:385–92
   PubMed Web of Science ®Google Scholar
• Forssen EA, Tökes ZA. (1983). Improved therapeutic benefits of doxorubicin by entrapment in anionic liposomes. Cancer Res 43:546–50
   PubMed Web of Science ®Google Scholar
• Gabizon AA, Shmeeda H, Zalipsky S. (2006). Pros and cons of the liposome platform in cancer drug targeting. J Liposome Res 16:175–83
   PubMed Web of Science ®Google Scholar
• Gao J, Liu W, Xia Y, et al. (2011). The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes. Biomaterials 32:3459–70
   PubMed Web of Science ®Google Scholar
• Gao J, Zhong W, He J, et al. (2009). Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes. Int J Pharm 374:145–52
   PubMed Web of Science ®Google Scholar
• Gasco MR. Method for producing solid lipid microspheres having a narrow size distribution. U.S. Patent No. 5,250,236; 5 Oct. 1993
   Google Scholar
• Ghanbarzadeh S, Khorrami A, Mohamed Khosroshahi L, Arami S. (2014). Fusogenic pH sensitive liposomal formulation for rapamycin: improvement of antiproliferative effect. Pharm Biol 52:848–54
   PubMed Web of Science ®Google Scholar
• Gharib A, Faezizadeh Z, Mesbah-Namin SAR, Saravani R. (2014). Preparation, characterization and in vitro efficacy of magnetic nanoliposomes containing the artemisinin and transferrin. Daru 22:44
   PubMed Web of Science ®Google Scholar
• Groopman JE, Itri LM. (1999). Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91:1616–34
   PubMed Web of Science ®Google Scholar
• Gu FX, Karnik R, Wang AZ, et al. (2007). Targeted nanoparticles for cancer therapy. Nano Today 2:14–21
   Web of Science ®Google Scholar
• Gubernator J, Lipka D, Korycińska M, et al. (2014). Efficient human breast cancer xenograft regression after a single treatment with a novel liposomal formulation of epirubicin prepared using the EDTA ion gradient method. PLoS One 9:e91487
   PubMed Web of Science ®Google Scholar
• Gulati M, Grover M, Singh S, Singh M. (1998). Lipophilic drug derivatives in liposomes. Int J Pharm 165:129–68
   Web of Science ®Google Scholar
• Guo S, Wang Y, Miao L, et al. (2014). Turning a water and oil insoluble cisplatin derivative into a nanoparticle formulation for cancer therapy. Biomaterials 35:7647–53
   PubMed Web of Science ®Google Scholar
• Gupta AK, Gupta M, Yarwood SJ, Curtis AS. (2004). Effect of cellular uptake of gelatin nanoparticles on adhesion, morphology and cytoskeleton organisation of human fibroblasts. J Control Release 95:197–207
   PubMed Web of Science ®Google Scholar
• Hadinoto K, Sundaresan A, Cheow WS. (2013). Lipid–polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review. Eur J Pharm Biopharm 85:427–43
   PubMed Web of Science ®Google Scholar
• Haley B, Frenkel E. (2008). Nanoparticles for drug delivery in cancer treatment. Urol Oncol 26:57–64
   PubMed Web of Science ®Google Scholar
• Harush-Frenkel O, Debotton N, Benita S, Altschuler Y. (2007). Targeting of nanoparticles to the clathrin-mediated endocytic pathway. Biochem Biophys Res Commun 353:26–32
   PubMed Web of Science ®Google Scholar
• Hashem FM, Nasr M, Khairy A. (2013). In vitro cytotoxicity and bioavailability of solid lipid nanoparticles containing tamoxifen citrate. Pharm Dev Technol 19:824–32
   PubMed Web of Science ®Google Scholar
• He Y, Zhang L, Song C. (2010). Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomes. Int J Nanomed 5:697
   PubMed Web of Science ®Google Scholar
• Hillaireau H, Couvreur P. (2009). Nanocarriers’ entry into the cell: relevance to drug delivery. Cell Mol Life Sci 66:2873–96
   PubMed Web of Science ®Google Scholar
• How CW, Rasedee A, Manickam S, Rosli R. (2013). Tamoxifen-loaded nanostructured lipid carrier as a drug delivery system: characterization, stability assessment and cytotoxicity. Colloid Surf B Biointerfaces 112:393–9
   PubMed Web of Science ®Google Scholar
• Iqbal MA, Md S, Sahni JK, et al. (2012). Nanostructured lipid carriers system: recent advances in drug delivery. J Drug Target 20:813–30
   PubMed Web of Science ®Google Scholar
• Iversen T-G, Skotland T, Sandvig K. (2011). Endocytosis and intracellular transport of nanoparticles: present knowledge and need for future studies. Nano Today 6:176–85
   Web of Science ®Google Scholar
• Jain AS, Goel PN, Shah SM, et al. (2014). Tamoxifen guided liposomes for targeting encapsulated anticancer agent to estrogen receptor positive breast cancer cells: in vitro and in vivo evaluation. Biomed Pharmacother 68:429–38
   PubMed Web of Science ®Google Scholar
• Jones AT. (2007). Macropinocytosis: searching for an endocytic identity and role in the uptake of cell penetrating peptides. J Cell Mol Med 11:670–84
   PubMed Web of Science ®Google Scholar
• Kaufmann M, Jonat W, Hilfrich J, et al. (2007). Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol 25:2664–70
   PubMed Web of Science ®Google Scholar
• Kaur T, Slavcev R. (2013). Solid lipid nanoparticles: tuneable anti-cancer gene/drug delivery systems. [Online] Available at: cdn.intechopen.com [last accessed 13 Feb 2013]
   Google Scholar
• Koch U, Krause M, Baumann M. (2010). Cancer stem cells at the crossroads of current cancer therapy failures - radiation oncology perspective. Semin Cancer Biol 20:116–24
   PubMed Web of Science ®Google Scholar
• König J, van Ewijk R, Kuhr K, et al. (2015). Radiotherapy effects on early breast cancer survival in observational and randomized studies: a systematic analysis of advantages, disadvantages and differences between the two study types. Breast Cancer. [Epub ahead of print]. doi: 10.1007/s12282-014-0579-2
   PubMedGoogle Scholar
• Kumar S, Randhawa JK. (2013). High melting lipid based approach for drug delivery: solid lipid nanoparticles. Mater Sci Engg C 33:1842–52
   Web of Science ®Google Scholar
• Lammers T, Hennink W, Storm G. (2008). Tumour-targeted nanomedicines: principles and practice. Br J Cancer 99:392–7
   PubMed Web of Science ®Google Scholar
• Lammers T, Kiessling F, Hennink WE, Storm G. (2012). Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release 161:175–87
   PubMed Web of Science ®Google Scholar
• Lee M-K, Lim S-J, Kim C-K. (2007). Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials 28:2137–46
   PubMed Web of Science ®Google Scholar
• Lin M, Teng L, Wang Y, et al. (2015). Curcumin-guided nanotherapy: a lipid-based nanomedicine for targeted drug delivery in breast cancer therapy. Drug Deliv. [Epub ahead of print]. DOI: 10.3109/10717544.2015.1066902
   Google Scholar
• Liu D, Liu Z, Wang L, et al. (2011). Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf B Biointerfaces 85:262–9
   PubMed Web of Science ®Google Scholar
• Liu Q, Li J, Pu G, et al. (2015). Co-delivery of baicalein and doxorubicin by hyaluronic acid decorated nanostructured lipid carriers for breast cancer therapy. Drug Deliv. [Epub ahead of print]. DOI: 10.3109/10717544.2015.1031295
   Google Scholar
• Liu Y, Li K, Pan J, et al. (2010). Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of Docetaxel. Biomaterials 31:330–8
   PubMed Web of Science ®Google Scholar
• Luo Q, Zhao J, Zhang X, Pan W. (2011). Nanostructured lipid carrier (NLC) coated with Chitosan Oligosaccharides and its potential use in ocular drug delivery system. Int J Pharm 403:185–91
   PubMed Web of Science ®Google Scholar
• Maeda H, Wu J, Sawa T, et al. (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65:271–84
   PubMed Web of Science ®Google Scholar
• Mamot C, Ritschard R, Wicki A, et al. (2012). Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells. J Drug Target 20:422–32
   PubMed Web of Science ®Google Scholar
• Mandal B, Bhattacharjee H, Mittal N, et al. (2013). Core–shell-type lipid–polymer hybrid nanoparticles as a drug delivery platform. Nanomed Nanotechnol Biol Med 9:474–91
   PubMed Web of Science ®Google Scholar
• Mattu C, Pabari R, Boffito M, et al. (2013). Comparative evaluation of novel biodegradable nanoparticles for the drug targeting to breast cancer cells. Eur J Pharm Biopharm 85:463–72
   PubMed Web of Science ®Google Scholar
• Medina-Kauwe LK. (2007). “Alternative” endocytic mechanisms exploited by pathogens: new avenues for therapeutic delivery? Adv Drug Deliv Rev 59:798–809
   PubMed Web of Science ®Google Scholar
• Mercer J, Helenius A. (2009). Virus entry by macropinocytosis. Nat Cell Biol 11:510–20
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hunter AC, Murray JC. (2005). Nanomedicine: current status and future prospects. FASEB J 19:311–30
   PubMed Web of Science ®Google Scholar
• Morad SA, Levin JC, Shanmugavelandy SS, et al. (2012). Ceramide–antiestrogen nanoliposomal combinations - novel impact of hormonal therapy in hormone-insensitive breast cancer. Mol Cancer Ther 11:2352–61
   PubMed Web of Science ®Google Scholar
• Muèller RH, Maèder K, Gohla S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm 50:161–77
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Ray S, Thakur R. (2009). Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci 71:349
   PubMed Web of Science ®Google Scholar
• Müller R, Radtke M, Wissing S. (2002a). Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 242:121–8
   PubMed Web of Science ®Google Scholar
• Müller R, Radtke M, Wissing S. (2002b). Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 54:S131–55
   PubMed Web of Science ®Google Scholar
• Nishikawa K, Asai T, Shigematsu H, et al. (2012). Development of anti-HB-EGF immunoliposomes for the treatment of breast cancer. J Control Release 160:274–80
   PubMed Web of Science ®Google Scholar
• Nourbakhsh M, Jaafari MR, Lage H, Abnous K. (2015). Nanolipoparticles-mediated MDR1 siRNA delivery reduces doxorubicin resistance in breast cancer cells and silences MDR1 expression in xenograft model of human breast cancer. Iran J Basic Medical Sci 18:385
   PubMed Web of Science ®Google Scholar
• Paliwal SR, Paliwal R, Mishra N, et al. (2010). A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy. Curr Cancer Drug Targets 10:343–53
   PubMed Web of Science ®Google Scholar
• Papa A-L, Sidiqui A, Balasubramanian SUA, et al. (2013). PEGylated liposomal Gemcitabine: insights into a potential breast cancer therapeutic. Cell Oncol 36:449–57
   Web of Science ®Google Scholar
• Patidar A, Thakur DS, Kumar P, Verma J. (2010). A review on novel lipid based nanocarriers. Int J Pharm Pharmaceut Sci 2:30–5
   Google Scholar
• Phillips MA, Gran ML, Peppas NA. (2010). Targeted nanodelivery of drugs and diagnostics. Nano Today 5:143–59
   PubMed Web of Science ®Google Scholar
• Pirollo KF, Chang EH. (2008). Targeted delivery of small interfering RNA: approaching effective cancer therapies. Cancer Res 68:1247–50
   PubMed Web of Science ®Google Scholar
• Polisena C, ed. (2000). Nutrition concerns with the radiation therapy patient. In: The Clinical Guide to Oncology Nutrition. Chicago: The American Dietetic Association, 70–8
   Google Scholar
• Qin C, He B, Dai W, et al. (2014). Inhibition of metastatic tumor growth and metastasis via targeting metastatic breast cancer by chlorotoxin-modified liposomes. Mol Pharm 11:3233–41
   PubMed Web of Science ®Google Scholar
• Ramadass SK, Anantharaman NV, Subramanian S, et al. (2015). Paclitaxel/Epigallocatechin gallate coloaded liposome: a synergistic delivery to control the invasiveness of MDA-MB-231 breast cancer cells. Colloids Surf B Biointerfaces 125:65–72
   PubMed Web of Science ®Google Scholar
• Rappoport J. (2008). Focusing on clathrin-mediated endocytosis. Biochem J 412:415–23
   PubMed Web of Science ®Google Scholar
• Reddy BS, Banerjee R. (2005). 17β-Estradiol-associated stealth-liposomal delivery of anticancer gene to breast cancer cells. Angew Chemie 117:6881–5
   Google Scholar
• Sahay G, Alakhova DY, Kabanov AV. (2010). Endocytosis of nanomedicines. J Control Release 145:182–95
   PubMed Web of Science ®Google Scholar
• Saupe A, Gordon KC, Rades T. (2006). Structural investigations on nanoemulsions, solid lipid nanoparticles and nanostructured lipid carriers by cryo-field emission scanning electron microscopy and Raman spectroscopy. Int J Pharm 314:56–62
   PubMed Web of Science ®Google Scholar
• Schlotter CM, Vogt U, Allgayer H, Brandt B. (2008). Molecular targeted therapies for breast cancer treatment. Breast Cancer Res 10:211
   PubMed Web of Science ®Google Scholar
• Shete H, Chatterjee S, De A, Patravale V. (2013). Long chain lipid based tamoxifen NLC. Part II: pharmacokinetic, biodistribution and in vitro anticancer efficacy studies. Int J Pharm 454:584–92
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–92
   PubMed Web of Science ®Google Scholar
• Sun M, Nie S, Pan X, et al. (2014). Quercetin-nanostructured lipid carriers: characteristics and anti-breast cancer activities in vitro. Colloids Surf B Biointerfaces 113:15–24
   PubMed Web of Science ®Google Scholar
• Tan BJ, Quek KS, Wong M-Y, et al. (2010). Liposomal MV-05: formulation development and activity testing of a novel dihydrofolate reductase inhibitor for breast cancer therapy. Int J Oncol 37:211–18
   PubMed Web of Science ®Google Scholar
• Tanaka T, Decuzzi P, Cristofanilli M, et al. (2009). Nanotechnology for breast cancer therapy. Biomed Microdev 11:49–63
   PubMed Web of Science ®Google Scholar
• Umesono K, Evans RM. (1989). Determinants of target gene specificity for steroid/thyroid hormone receptors. Cell 57:1139–46
   PubMed Web of Science ®Google Scholar
• Vodovozova E, Moiseeva E, Grechko G, et al. (2000). Antitumour activity of cytotoxic liposomes equipped with selectin ligand SiaLe X, in a mouse mammary adenocarcinoma model. Eur J Cancer 36:942–9
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Layard MW, Basa P, et al. (1979). Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710–17
   PubMed Web of Science ®Google Scholar
• Wang S, Chen T, Chen R, et al. (2012). Emodin loaded solid lipid nanoparticles: preparation, characterization and antitumor activity studies. Int J Pharm 430:238–46
   PubMed Web of Science ®Google Scholar
• Waterhouse DN, Denyssevych T, Hudon N, et al. (2005). Trastuzumab and liposomal Doxorubicin in the treatment of mcf-7 xenograft tumor-bearing mice: combination does not affect drug serum levels. Pharm Res 22:915–22
   PubMed Web of Science ®Google Scholar
• Waterhouse DN, Tardi PG, Mayer LD, Bally MB. (2001). A comparison of liposomal formulations of doxorubicin with drug administered in free form. Drug Saf 24:903–20
   PubMedGoogle Scholar
• Westesen K, Siekmann B. (1996). Biodegradable colloidal drug carrier systems based on solid lipids. Drugs Pharmaceut Sci 73:213–58
   Google Scholar
• Wissing S, Kayser O, Müller R. (2004). Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 56:1257–72
   PubMed Web of Science ®Google Scholar
• Wong HL, Bendayan R, Rauth AM, Wu XY. (2006a). Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J Control Release 116:275–84
   PubMed Web of Science ®Google Scholar
• Wong HL, Bendayan R, Rauth AM, et al. (2006b). A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. J Pharmacol Exp Ther 317:1372–81
   PubMed Web of Science ®Google Scholar
• Wong HL, Bendayan R, Rauth AM, et al. (2007). Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev 59:491–504
   PubMed Web of Science ®Google Scholar
• Wong HL, Rauth AM, Bendayan R, et al. (2006c). A new polymer–lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm Res 23:1574–85
   PubMed Web of Science ®Google Scholar
• Yaghmur A, Glatter O. (2009). Characterization and potential applications of nanostructured aqueous dispersions. Adv Colloid Interface Sci 147:333–42
   PubMed Web of Science ®Google Scholar
• Yang T, Choi M-K, Cui F-D, et al. (2007). Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J Control Release 120:169–77
   PubMed Web of Science ®Google Scholar
• Yang Z, Luo X, Zhang X, et al. (2013). Targeted delivery of 10-hydroxycamptothecin to human breast cancers by cyclic RGD-modified lipid–polymer hybrid nanoparticles. Biomed Mater 8:025012
   PubMed Web of Science ®Google Scholar
• Yuan H, Miao J, Du Y-Z, et al. (2008). Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int J Pharm 348:137–45
   PubMed Web of Science ®Google Scholar
• Yuan Q, Han J, Cong W, et al. (2014). Docetaxel-loaded solid lipid nanoparticles suppress breast cancer cells growth with reduced myelosuppression toxicity. Int J Nanomed 9:4829
   PubMed Web of Science ®Google Scholar
• Zhang H, Gong W, Wang ZY, et al. (2014). Preparation, characterization, and pharmacodynamics of thermosensitive liposomes containing Docetaxel. J Pharm Sci 103:2177–83
   PubMed Web of Science ®Google Scholar
• Zhang L, Chan JM, Gu FX, et al. (2008a). Self-assembled lipid– polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano 2:1696–702
   PubMed Web of Science ®Google Scholar
• Zhang P, Ling G, Pan X, et al. (2012). Novel nanostructured lipid-dextran sulfate hybrid carriers overcome tumor multidrug resistance of mitoxantrone hydrochloride. Nanomed Nanotechnol Biol Med 8:185–93
   PubMed Web of Science ®Google Scholar
• Zhang X-G, Miao J, Dai Y-Q, et al. (2008b). Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells. Int J Pharm 361:239–44
   PubMed Web of Science ®Google Scholar
• Zhang YJ, Gallis B, Taya M, et al. (2013). pH-Responsive artemisinin derivatives and lipid nanoparticle formulations inhibit growth of breast cancer cells in vitro and induce down-regulation of HER family members. PLoS One 8:e59086
   Google Scholar
• Zhao Y-Z, Dai D-D, Lu C-T, et al. (2013). Epirubicin loaded with propylene glycol liposomes significantly overcomes multidrug resistance in breast cancer. Cancer Lett 330:74–83
   PubMed Web of Science ®Google Scholar